| abstract |
The present invention relates to human cellular protein kinases, metalloproteases and one phosphatase: beta-adrenergic receptor kinase 1 (NM 001619), Mitogen activated protein kinase activated protein kinase 5 (AF032437), Insulin-stimulated protein kinase 1 (U08316), Discoidin domain receptor family, member 1(NM 013994), Protein Kinase C, mu (X75756), Protein Kinase C, theta (L01087), AMP-activated protein kinase beta 2 subunit (AJ 224538), JNK2 (U09759), Human p21-activated protein kinase 2 (U24153), cyclin-dependent kinase 4 (U37022), MEK5 (U25265), MKP-L (NM 007026), ADAM22 (NM 016351), and ADAM17 (U92649) as potential targets for medical intervention against Hepatitis C virus (HCV) infections. The present invention relates also to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C virus infections, a method for detecting Hepatitis C virus infections in an individual or in cells. Mono- or polyclonal antibodies are disclosed effective for the treatment of HCV infections together with methods for treating Hepatitis C virus infections or for the regulation of Hepatitis C virus production and/or replication wherein said antibodies may be used. Finally the present invention relates to a solid support useful for detecting Hepatitis C virus infections or for screening compounds useful for prophylaxis and/or treatment of HCV infections. |